Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial

Journal:
Nature Medicine
Published:
DOI:
10.1038/s41591-025-04182-9
Affiliations:
11
Authors:
29
Go to article
Institutions Authors Share
The University of Texas MD Anderson Cancer Center, United States of America (USA)
13.000000
13.000000
 0.45
Nouscom Srl, Italy
8.000000
 0.28
NIH National Cancer Institute (NCI), United States of America (USA)
2.500000
 0.09
University of Puerto Rico (UPR), United States of America (USA)
2.000000
 0.07
Fox Chase Cancer Center (FCCC), United States of America (USA)
1.000000
 0.03
City of Hope Comprehensive Cancer Center, United States of America (USA)
1.000000
 0.03
Nouscom AG, Switzerland
1.000000
 0.03
USN Walter Reed National Military Medical Center (WRNMMC), United States of America (USA)
0.500000
 0.02
Interested in Oncology and Carcinogenesis?